This clinical trial aims to evaluate the efficacy and safety of a new investigational drug for treating moderate to severe asthma in adults. Participants will be randomly assigned to receive either the investigational drug or a placebo, and neither the participants nor the researchers will know which treatment is being administered. The study will help determine if the investigational drug can improve lung function and reduce asthma symptoms compared to the placebo.

• Who Can Participate: Adults aged 18-65 with a diagnosis of moderate to severe asthma, who are non-smokers and have not participated in another clinical trial in the last 30 days
• Study Details: The trial will last for 12 weeks, during which participants will attend clinic visits every two weeks for assessments and monitoring
• Study Timelines and Visits: The study is expected to start in January 2024 and conclude by April 2024.Participants will attend a total of 6 clinic visits over the 12-week study period